This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
High-risk compound
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Browse
Mod GRF 1-29
Short-half-life GHRH analog.
Aliases (5)
modified GRF 1-29 · sermorelin without DAC · tetrasubstituted GHRH 1-29 · CJC-1295 no DAC · CJC-1295 without DAC
TYPICAL DOSE
—
ROUTE
—
CYCLE
—
STORAGE
—
Overview
What is Mod GRF 1-29?
Short-half-life GHRH analog. Mimics pulsatile GH secretion better than CJC-1295 with DAC. Common "anti-aging" peptide stack with ipamorelin. WADA-banned. SKIP-FOR-NOW for healthy 20yo.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Was this helpful?
Your feedback shapes what we research deeper.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
Loading…
✎
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.
Discussion — click to load ▸
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources
Related compounds
Cross-referenced from Mod GRF 1-29Sermorelin
SKIP-FOR-NOW
Truncated GHRH analog — synthetic 29-amino-acid peptide identical to the bioactive N-terminal fragment of native human growth-hormone-releasing hormone. Pituitary GH secretagogue. Originally FDA-approved (Geref) for pediatric growth hormone deficiency (1990) and as a diagnostic for GH-axis function (Geref Diagnostic, 1997). Both approvals voluntarily withdrawn by Serono in 2008 for commercial reasons (small market). Currently no FDA-approved sermorelin product on the US market; widely available via 503A compounding pharmacies and gray-market peptide vendors.
MEDIUM-HIGH
CJC-1295
SKIP-FOR-NOW
Modified GHRH(1-29) analog with Drug Affinity Complex (DAC) for albumin conjugation; long-acting growth hormone secretagogue. (CJC-1295 "no DAC" / "Modified GRF 1-29" is the same 4-amino-acid-modified GHRH(1-29) without the MPA-lysine extension and is functionally a different drug — short half-life pulsatile GHRH analog.)
MEDIUM
Ipamorelin
SKIP-FOR-NOW
Growth hormone-releasing peptide (GHRP family) — selective GHS-R1a (ghrelin receptor) agonist; pentapeptide
MEDIUM
GHRP-2
SKIP-FOR-NOW
Growth hormone-releasing peptide (GHRP family) — non-selective GHS-R1a (ghrelin receptor) agonist; synthetic hexapeptide. Older-generation GHRP (1990s development) preceding the selective compounds (ipamorelin).
MEDIUM
GHRP-6
SKIP-FOR-NOW
Growth hormone-releasing peptide (first-generation GHRP family) — non-selective GHS-R1a (ghrelin receptor) agonist; hexapeptide. Predecessor to GHRP-2 and ipamorelin. Strong gut-ghrelin-mimetic appetite stimulant.
MEDIUM
Hexarelin
SKIP-FOR-NOW
Growth hormone-releasing peptide (GHRP family) — non-selective GHS-R1a agonist; hexapeptide. Methylated tryptophan analog of GHRP-6 with significantly higher GH-releasing potency.
MEDIUM
Tesamorelin
SKIP-FOR-NOW
"Stabilized GHRH(1-44) analog — 44-amino-acid synthetic growth-hormone-releasing hormone with N-terminal trans-3-hexenoyl modification protecting against DPP-IV cleavage. FDA-approved for HIV-associated lipodystrophy (only FDA-approved GH-axis peptide for visceral fat reduction). Sponsor: Theratechnologies (Montreal). Manufactured by Bachem."
MEDIUM
HGH (Human Growth Hormone)
SKIP-FOR-NOW
"191-amino-acid recombinant human growth hormone — direct exogenous replacement of pituitary-secreted GH; full agonist at the GH receptor (GHR). Distinct from every other GH-axis compound on this wiki: GHRH analogs (sermorelin, tesamorelin, CJC-1295) and GH secretagogues (ipamorelin, MK-677, GHRP-2/6) all act upstream at the pituitary to release endogenous GH; HGH is the GH itself, bypassing the entire hypothalamic-pituitary feedback loop."
HIGH